Nanjing Pharmaceutical Company Limited’s Net Profit Rose 45.4% in First Half of 2022

Nanjing Pharmaceutical Company Limited (南京医药股份有限公司) (600713.SH) reported a net profit of 390.1 million yuan in the first half of 2022, up 45.4% year-on-year.

Meanwhile, the company posted 23.9 billion yuan in revenue, up 9.3% year-on-year.

At the end of the reporting period, it had 27.7 billion yuan in total assets and 21.3 billion yuan in total liabilities, with a liability-to-asset ratio of 76.9%.